Tim Smith

These data highlight the frequency of adverse events with narrow-band UVB phototherapy and concomitant therapy.

Despite these conclusions, this meta-analysis also showed that those receiving PDE4 inhibitors were the least likely to report adverse events.

The FDA approval of benralizumab for patients ages 6 to 11 with asthma follows the conclusions of the phase 3 TATE study.

This analysis was conducted to address the fact that, while there are various acne specific instruments to assess quality of life domains, none exist to focus on all of the domains.

These data highlight the benefits and drawbacks of the STAR and GOLD severity classification systems for COPD patients.

This study’s investigators point to the necessity of adapting an antibiotic stewardship program for acne treatment, with evaluation being done in dermatology practices to assess performance.

In the latest Lungcast, Drs. McCurry and Valapour answered several questions on the candidacy of post-infectious COVID-19 patients for lung transplantation and on long COVID.

These nationwide data contribute to the overall body of research on extraintestinal inflammatory conditions among MC patients, highlighting the value of studying the mechanisms involved.

In these data, investigators had investigated the international differences in topical AK medication implementation, including links to countries’ different economic statuses.

This analysis highlights trends following the significant update made to the Global Initiative for Asthma and the National Heart Lung and Blood Institute asthma guidelines.

During this segment of Lungcast, Valapour and McCurry discussed recent changes made to lung allocation scores as well as the topic of graft rejection.

These data add to the growing body of literature on the impacts of different types of air pollution on respiratory conditions such as COPD and asthma.

The FDA announcement on bimekizumab’s supplemental Biologics License Application followed the phase 3 BE HEARD I and II studies’ conclusion.

This analysis was conducted to evaluate the burden and disease characteristics of all 3 types of HAE among a set of Canadian patients.

In this Month in Review article for March, news on topics such as asthma and the impacts of pollution in the pulmonology field were highlighted.

These data may have impactful clinical and health policy implications, given that hospitalizations for CAP are known to be common and given the frequency of incorrect diagnoses.

This meta-analysis demonstrates the possibilities for probiotic supplementation, though additional multi-center clinical studies with larger samples may be needed.

This post-hoc analysis of clinical and real-world settings looks at both both biologic-naïve and bio-experienced individuals.

The application for generic roflumilast cream, 0.3%, for plaque psoriasis may end up entitling Padagis to 180 days of market exclusivity.

In this review of the top stories in dermatology in March, several were highlighted such as the recent report on benzene in skincare products and the FDA’s approval of spesolimab for generalized pustular psoriasis.

This post-AAD interview with Chovatiya covered takeaways regarding recent data on upadacitinib for vitiligo, tapinarof for eczema, and lutikizumab for hidradenitis suppurativa.

In this interview segment, Del Rosso further explores the steps patients and clinicians should take in considering the recent Valisure report on benzene risk for skincare products with benzoyl peroxide.

In this interview, Del Rosso expresses his personal views on the recent report of benzene in benzoyl peroxide acne products.

Chovatiya spoke in this post-AAD interview to some of the major takeaways in psoriasis research, highlighting deucravacitinib, bimekizumab, and other therapies.

The investigators seek to replicate the data in a future randomized control trial, and they hope to compare biofeedback to different therapies such as pulmonary rehabilitation.

Following this analysis, the conclusions provide more information on the views of potential dermatology patients on the future of their own medical images by artificial intelligence systems.

These data highlight the changes observed in cytokine levels among both PsA treatment responders and non-responders.

In this analysis from the UK, the DDPS led to improved pathway management which also achieved lower service demand and smaller waiting lists for dermatologists.

In this new research, different populations of Black and Latinx individuals are facing long-term impacts of air pollution in the city of Austin.

These data suggest risankizumab was both safe and efficacious through 100 weeks for PsA patients, with no new safety signals.